USPTO serial 90058343
NOWCHECK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 13, 2022
- Examiner
- BICE, DANIEL TRAVIS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NOWCHECK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Hwaseong Gyeonggi, KR
Hwaseong Gyeonggi, KR
Hwaseong Gyeonggi, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David D'Zurilla
David D'Zurilla SCHWEGMAN, LUNDBERG & WOESSNER, P.A.P.O. BOX 2938MINNEAPOLIS, MN 55402UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | clinical diagnostic reagents for scientific or research use, not for medical or veterinary use; domestic pregnancy diagnostic agents for scientific or research use, not for medical or veterinary use; tuberculosis diagnostic reagents for scientific or research use, not for medical or veterinary use | ACTIVE | — |
| 005 | Medical and veterinary biologics in the nature of biological tissue, namely, body fluids, blood, nasopharyngeal specimens, nasal specimens, saliva, conjunctival specimens, and urine specimens for medical and veterinary purposes; medical diagnostic reagents,; medical and veterinary diagnostic reagents and media, medical reagents, domestic pregnancy diagnostic agents for medical purposes, tuberculosis diagnostic reagents for medical purposes, vaccines, vaccine supplements, and bacteriological culture mediums, medical enzymes; Pregnancy test kits for home use being domestic pregnancy diagnostic agents; cell test device in the nature of medical diagnostic test kits for testing cancer cells comprised of diagnostic reagents; urine tester in the nature of medical diagnostic test kits for the analysis of urine comprised of diagnostic reagents; kidney function test equipment in the nature of medical diagnostic test kits for the analysis of body fluids comprised of diagnostic reagents; medical immunity test device in the nature of medical diagnostic test kits for the analysis of body fluids comprised of diagnostic reagents; medical immunofluorescence analysis device in the nature of medical diagnostic test kits for the analysis of body fluids comprised of diagnostic reagents; medical diagnostic immunoassay device in the nature of medical diagnostic test kits for the analysis of body fluids comprised of diagnostic reagents; diagnostic blood analysis device in the nature of medical diagnostic test kits for the analysis of various biomarkers in blood for diagnostic purposes comprised of diagnostic reagents; in vitro diagnostic device in the nature of medical diagnostic test kits for the analysis of body fluids comprised of diagnostic reagents; all of the foregoing excluding reagents and devices for use in blood glucose monitoring and diabetes care | ACTIVE | — |
| 009 | Research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids, namely, arteriosclerosis diagnostic instrument, ovulation measuring instrument, diagnostic test execution device for detecting modified abnormal prion protein, urine tester, and kidney function test equipment; Laboratory devices for detecting genetic sequences, namely, genetic tester and small miniaturized sensor for gene analysis and diagnosis, not for medical or veterinary purposes; Medical laboratory research instruments for testing genetics, namely, medical genetic test device for laboratory and scientific use, not for medical or veterinary use | ACTIVE | — |
| 010 | Medical equipment, other than for dental purposes, in the nature of medical diagnostic test instruments using chromatographic techniques for analysis of body fluid, arteriosclerosis diagnostic instrument for medical purposes, ovulation measuring instrument for medical purposes, diagnostic test execution device for detecting modified abnormal prion protein for medical purposes, bacteria and virus tester in the nature of medical diagnostic instruments for the analysis of body fluids, cell test device in the nature of medical diagnostic instruments for testing cancer cells, urine tester in the nature of medical diagnostic instruments for the analysis of urine, kidney function test equipment in the nature of medical diagnostic instruments for the analysis of body fluids, Medical measuring device for cancer diagnosis, genetic tester in the nature of Point of Care system apparatus using isothermal amplification and polymerase chain reaction technology for DNA and RNA testing for medical diagnostic purposes, small miniaturized sensor for gene analysis and diagnosis in the nature of Point of Care system apparatus for DNA and RNA testing for medical diagnostic purposes, medical immunity test device in the nature of medical diagnostic instruments for the analysis of body fluids, medical immunofluorescence analysis device in the nature of medical diagnostic instruments for the analysis of body fluids, medical genetic test device in the nature of Point of Care system apparatus for DNA and RNA testing for medical diagnostic purposes, medical diagnostic immunoassay device in the nature of medical diagnostic instruments for the analysis of body fluids, diagnostic blood analysis device in the nature of medical diagnostic instruments for the analysis of various biomarkers in blood for diagnostic purposes, in vitro diagnostic device in the nature of medical diagnostic instruments for the analysis of body fluids for medical purposes; all of the foregoing exluding instruments and devices for use in blood glucose monitoring and diabetes care | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioNote, Inc.
- Other trademarks owned by BioNote, Inc.
- Other trademarks owned by BioNote, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named NOWCHECK
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 13, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 13, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 7, 2022 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jun 7, 2022 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 7, 2022 | APET | ASSIGNED TO PETITION STAFF | — |
| May 19, 2022 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Apr 28, 2022 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Mar 29, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 29, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 9, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 23, 2022 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Feb 18, 2022 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Feb 11, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 11, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 11, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 11, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 11, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 13, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 13, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 13, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 7, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 3, 2021 | ALIE | ASSIGNED TO LIE | — |
| Nov 30, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 5, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Oct 5, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Oct 5, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 4, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 18, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 18, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 18, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 25, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 25, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 25, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 21, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 21, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 21, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 12, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 11, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 11, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 15, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 15, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 15, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 2, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 2, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 2, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 3, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 14, 2020 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 13, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 21, 2020 | NWAP | NEW APPLICATION ENTERED | — |